Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose

Vaccine

Volumn 30, Issue 5, 2012, Pages 974-982

  Halperin, Scott A ^a   Scheifele, David ^b   De Serres, Gaston ^c   Noya, Francisco ^d   Meekison, William ^e   Zickler, Paul ^f   Larrivée, Luc ^g   Langley, Joanne M ^a   McNeil, Shelly A ^a   Dobson, Simon ^b   Jordanov, Emilia ^h   Thakur, Manoj ^h   Decker, Michael D ^h   Johnson, David R ^h  

^a DALHOUSIE UNIVERSITY   (Canada)

^b BC CHILDREN S HOSPITAL   (Canada)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e RIVERVIEW HOSPITAL   (Canada)

^f TASC Research Services Inc   (Canada)

^g QandT Research   (Canada)

^h SANOFI PASTEUR   (France)

Author keywords

Acellular pertussis vaccine; Adult immunization; Diphtheria vaccine; Tetanus vaccine

Indexed keywords

ANTIBODY; ANTIGEN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; TDAP; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; DIPHTHERIA; DRUG SAFETY; ERYTHEMA; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; PAIN; PERTUSSIS; PRIORITY JOURNAL; REVACCINATION; SWELLING; TETANUS;

ADULT; AGED; ANTIBODIES, BACTERIAL; ANTITOXINS; CANADA; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; UNITED STATES;

EID: 84855463707     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.035     Document Type: Article

References (52)

1. Cherry J.D. The present and future control of pertussis. Clin Infect Dis 2010, 51:663-667.
2. Halperin S.A. Canadian experience with implementation of an acellular pertussis vaccine booster-dose program in adolescents: implications for the United States. Pediatr Infect Dis J 2005, 24:S141-S146.
3. Guiso N., Wirsing von König, Forsyth K., Tan T., Plotkin S.A. The global pertussis initiative: report from a round table meeting to discuss the epidemiology and detection of pertussis, Paris, France, 11-12 January 2010. Vaccine 2011, 29:1115-1121.
4. Wei S.C., Tatti K., Cushing K., Rosen J., Brown K., Cassiday P., et al. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin Infect Dis 2010, 51:315-321.
5. Barreto L., Guasparini R., Meekison W., Noya F., Young L., Mills E. Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine 2007, 25:8172-8179.
6. Galanis E., King A.S., Varughese P., Halperin S.A. Changing epidemiology and emerging risk groups for pertussis. Can Med Assoc J 2006, 174:451-452.
7. Brooks D.A., Clover R. Pertussis infection in the United States: role for vaccination of adolescents and adults. J Am Board Fam Med 2006, 19:603-611.
8. Mertsola J., Van Der Meeren O., He Q., Linko-Parvinen A., Ramakrishan G., Mannermaa L., et al. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis 2010, 51:656-662.
9. Andrews R., Herceg A., Roberts C. Pertussis notifications in Australia, 1991 to 1997. Commun Dis Intell 1997, 21:145-148.
10. Berger F., Njamkepo E., Minaberry S., Mayet A., Haus-Cheymol R., Verret C., et al. Investigation on a pertussis outbreak in a military school: risk factors and approach to vaccine efficacy. Vaccine 2010, 28:5147-5152.
11. Hochwald O., Bamberger E.S., Rubin L., Gershtein R., Srugo I. A pertussis outbreak among daycare children in Northern Israel: who gets sick?. Isr Med Assoc J 2010, 12:283-286.
12. Baugh V., McCarthy N. Outbreak of Bordetella pertussis among oncology nurse specialists. Occup Med 2010, 60:401-405.
13. Waters V., Jamieson F., Richardson S.E., Finkelstein M., Wormsbecker A., Halperin S.A. Outbreak of atypical pertussis detected by polymerase chain reaction in immunized preschool-aged children. Pediatr Infect Dis J 2009, 28:582-587.
14. Centers for Disease Control and Prevention (CDC) Use of mass Tdap vaccination to control an outbreak of pertussis in a high school-Cook County, Illinois, September 2006-January 2007. Morb Mortal Wkly Rep 2008, 57:796-799.
15. de Greeff S.C., de Melker H.E., van Gageldonk P.G.M., Schellekens J.F.P., van der Klis F.R.M., Mollema L., et al. Seroprevalance of pertussis in the Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS ONE 2010, 5:e14183.
16. National Advisory Committee on Immunization (NACI) Prevention of pertussis in adolescents and adults. Can Commun Dis Rep 2003, 29(ACS-5,6):1-9.
17. Centers for Disease Control and Prevention (CDC) Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. MMWR Recomm Rep 2006, 55(RR3):1-50.
18. Centers for Disease Control and Prevention (CDC) Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR Recomm Rep 2006, 55(RR17):1-44.
19. Calendrier vaccinal détaillé 2008. Nouvelles recommandations. Vaccination contre la coqueluche. [accessed 02.10.11]. http://www.sante.gouv.fr/IMG/pdf/Calendrier_vaccinal_2008_-_nouvelles_recommandations.pdf.
20. Impfkalender. Epidemiologisches bulletin nr. 30. Robert Koch-Institut. [accessed 02.10.11]. http://www.rki.de/cln_100/nn_195844/DE/Content/Infekt/Impfen/STIKO/Empfehlungen/Aktuelles/Impfkalender,templateId=raw,property=publicationFile.pdf/Impfkalender.pdf.
21. Australian immunisation handbook, 9th ed. Pertussis. Australian Government Department of Health and Ageing, 2008. p. 227-39.
22. Ministère de la Santé [Ministry of Health]. Calendrier vaccinal recommandé au Luxembourg [Recommended immunization schedule in Luxembourg]. Portail Santé [Health Portal] [Internet]. Luxembourg: Ministère de la Santé [Ministry of Health]. Available from: 2011 Mar 18 [updated 18.03.11; cited 21.04.11]. http://www.sante.public.lu/fr/rester-bonne-sante/120-vaccinations/calendrier-vaccinal/index.html.
23. Impfausschuss [Vaccine Committee]. Impfplan 2011 österreich: Evidenz-basierte Empfehlungen des Obersten Sanitätsrates [Vaccination schedule in 2011 Austria: evidence-based recommendations of the National Health Council] [Internet]. Austria: Bundesministerium für Gesundheit [Federal Ministry of Health]. 38 p. Available from: 2010 Oct 12 [cited 21.04.11] [in German]. http://www.bmg.gv.at/cms/home/attachments/7/3/0/CH1081/CMS1286449898381/impfplan_2011.pdf.
24. de Carvalho A.P., Pereira E.M. Acellular pertussis vaccine for adolescents. J Pediatr (Rio J) 2006, 82(3 Suppl):S15-S24.
25. Singhal T. Indian Academy of Pediatrics Committee on Immunization (IAPCOI). Consensus recommendations on immunization, 2008. Indian Pediatr 2008, 45:635-648.
26. World Health Organization (WHO). Regional consultation to standardize EPI schedule in the Eastern Mediterranean Region of the World Health Organization (WHO EMRO). Cairo, Egypt: VPI/EMRO; 2006. 23 p. Available from: 2008 Mar 20 [cited 18.03.11]. http://www.who.int/immunization/sage/3_EMRO_1_EPI_Schedule_Report.pdf.
27. Booy R., Van Der Meeren O., Ng S.P., Celzo F., Ramakrishnan G., Jacquet J.M. A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix™) is immunogenic and well tolerated in adults. Vaccine 2011, 29:45-50.
28. Edelman K., He Q., Mäkinen J., Sahlberg A., Haanperä M., Schuerman L., et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis 2007, 44:1271-1277.
29. Wendelboe A.M., Van Rie A., Salmaso S., Englund J.A. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005, 24(5 Suppl):S58-S61.
30. Edelman K.J., He Q., Makinen J.P., Haanpera M.S., Minh N.N.T., Schuerman L., et al. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis 2004, 39:179-185.
31. Jenkinson D. Duration of effectiveness of pertussis vaccine: Evidence from a 10 year community study. Br Med J 1988, 296:612-614.
32. Bailleux F., Coudeville L., Kolenc-Saban A., Bevilacqua J., Barreto L., André P. Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data. Vaccine 2008, 26:3903-3908.
33. Hallander H.O., Gustafsson L., Ljungman M., Storsaeter J. Pertussis antitoxin decay after vaccination with DTPa response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine 2005, 23:5359-5364.
34. Beytout J., Launay O., Guiso N., Fiquet A., Baudin M., Richard P., et al. Safety of Tdap-IPV given one month after TD-IPV booster in healthy young adults. Hum Vaccines 2009, 5:315-321.
35. Halperin S.A., Sweet L., Baxendale D., Neatby A., Rykers P., Smith B., et al. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?. Pediatr Infect Dis J 2006, 25:195-200.
36. Talbot E.A., Brown K.H., Kirkland K.B., Baughman A.L., Halperin S.A., Broder K.R. The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: Experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine 2010, 28:8001-8007.
37. David S.T., Hemsley C., Pasquali P.E., Larke B., Buxton J.A., Lior L.Y. Enhanced surveillance for vaccine-associated adverse events: dTap catch-up of high school students in Yukon. Can Commun Dis Rep 2005, 31:117-126.
38. National Advisory Committee on Immunization (NACI). Interval between administration of vaccines against diphtheria, tetanus, and pertussis. Can Commun Dis Rep 2005;31(ACS-8 and 9):17-22.
39. Halperin S.A., Smith B., Russell M., Scheifele D., Mills E., Hasselback P., et al. Adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr Infect Dis J 2000, 19:276-283.
40. Sanofi Pasteur. Adacel® [product monograph] [Internet]. Toronto (ON): Sanofi Pasteur; 2009, August. p. 1-51. Available from: https://www.vaccineshoppecanada.com/secure/pdfs/ca/ADACEL_E.pdf.
41. Halperin S.A., McNeil S., Langley J., Blatter M., Dionne M., Embree J., et al. Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose. Vaccine 2011, 29:8459-8465.
42. Knuf M., Vetter V., Celzo F., Ramakrishan G., Van Der Meeren O., Jacquet J.M. Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix (IPV). Hum Vaccine 2010, 6:554-561.
43. Salmaso S., Mastrantonio P., Tozzi A.E., Stefanelli P., Anemona A., Ciofi degli Atti M.L., et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 2001, 108:e81.
44. Lugauer S., Heininger U., Cherry J.D., Stehr K. Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. Eur J Pediatr 2002, 161:142-146.
45. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998, 16:1907-1916.
46. Cherry J.D., Gornbein J., Heininger U., Stehr K. A Search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998, 16:1901-1906.
47. Ward J.I., Cherry J.D., Chang S.J., Partridge S., Lee H., Treanor J., et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005, 353:1555-1563.
48. Greenberg D.P., Doemland M., Bettinger J.A., Scheifele D.W., Halperin S.A., IMPACT Investigators, et al. Epidemiology of pertussis and Haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: implications for disease prevention in the United States. Pediatr Infect Dis J 2009, 28:521-528.
49. Wirsing von König C.H., Halperin S., Riffelmann M., Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2002, 2:744-750.
50. Campins-Martí M., Cheng H.K., Forsyth K., Guiso N., Halperin S., Huang L.M., et al. Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine 2001, 20:641-646.
51. Forsyth K.D., Wirsing von Konig C.H., Tan T., Caro J., Plotkin S. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 2007, 25:2634-2642.
52. Frampton J.E., Keating G.M. Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (Boostrix™). A review of its use as a single-dose booster immunization. BioDrugs 2006, 20:371-389.